-

Kaskela Law LLC MERGER INVESTIGATION: Does $9.55 Per Share Represent Sufficient Cash Out Value for Carrols Restaurant Group, Inc. (NASDAQ: TAST) Shares for Investors?

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Carrols Restaurant Group, Inc. (NASDAQ: TAST) (“Carrols”) on behalf of the company’s shareholders.

On January 16, 2024, Carrols announced that it had agreed to be acquired by Restaurant Brands International Inc. at a price of $9.55 per share in cash. Following the closing of the proposed transaction, Carrols’ shareholders will be cashed out of their investment position and the company’s shares will no longer be publicly traded.

The investigation seeks to determine whether investors will be receiving sufficient consideration for their shares, and whether Carrols’ officers and/or directors breached their fiduciary duties or violated the securities laws in agreeing to sell the company at $9.55 per share. Notably, immediately prior to the announcement of the proposed transaction, at least one stock analyst was maintaining a price target for Carrols’ shares at $13.00 per share.

Carrols shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229–0750, or by email (skaskela@kaskelalaw.com / abell@kaskelalaw.com) or online at https://kaskelalaw.com/cases/carrols-restaurant-group/ , for additional information about this investigation and their legal rights and options with respect to this transaction.

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.

This notice may constitute attorney advertising in certain jurisdictions.

Contacts

D. Seamus Kaskela, Esq.
Adrienne Bell, Esq.
(888) 715–1740
(484) 229–0750
www.kaskelalaw.com

Kaskela Law LLC

NASDAQ:TAST

Release Versions

Contacts

D. Seamus Kaskela, Esq.
Adrienne Bell, Esq.
(888) 715–1740
(484) 229–0750
www.kaskelalaw.com

More News From Kaskela Law LLC

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of The Beauty Health Company (NASDAQ: SKIN) and Encourages Long-Term Shareholders to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating The Beauty Health Company (NASDAQ: SKIN) (“Beauty Health”) on behalf of the company’s shareholders. Click here for additional information: https://kaskelalaw.com/case/the-beauty-health-company/ Since March 2024, shares of Beauty Health’s common stock have declined in value from a trading price of approximately $4.50 per share to a current trading price of below $1.75 per share, a decline of over 60% in value. The...

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of DHI Group, Inc. (NYSE: DHX) and Encourages Long-Term Shareholders to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating DHI Group, Inc. (NYSE: DHX) (“DHI”) on behalf of the company’s shareholders. Click here for additional information: https://kaskelalaw.com/case/dhi-group/ Since January 2023, shares of DHI’s common stock have declined in value from a trading price of over $6.00 per share to a current trading price of below $3.00 per share, a decline of over 50% in value. The investigation seeks to determine whether DHI and/or the...

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) (“Amicus”) on behalf of the company’s shareholders. Click here for additional information: https://kaskelalaw.com/case/amicus-therapeutics/ Since December 2023, shares of Amicus’ common stock have declined in value from a trading price of $14.50 per share to a current trading price of approximately $11.00 per share, a decline of nearly 25% in value. The investigation seeks...
Back to Newsroom